Another well-established predictive biomarker is the oncogenic BCR-ABL gene fusion, which predicts for antitumor responses to the tyrosine kinase inhibitor imatinib in chronic myelogenous leukemia [31]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.